Travere Therapeutics Reports Q3 2026 Results Driven by FILSPARI Sales Growth
Travere Therapeutics (TVTX) reported strong third-quarter 2026 financial results, highlighted by total net product sales of $220.2 million, a significant increase from $113.2 million in the prior-year period. This growth was primarily fueled by FILSPARI, which saw net product sales reach $200.2 million—a 120% year-over-year increase driven by high demand in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) indications. Despite the revenue surge, the company reported a GAAP net loss of $52.3 million ($0.55 per share), compared to a profit in Q3 2025, largely due to increased IPR&D expenses related to licensing agreements. Management remains optimistic about long-term scaling, setting an annual sales target for FILSPARI of $3 billion or more by 2033 and maintaining a strong liquidity position with $471.8 million in cash and marketable securities.
Tickers: $TVTX
Topics: Focal segmental glomerulosclerosis GAAP Net Loss IgA nephropathy Net Product Sales Revenue Guidance